John Kelly - Atomo Diagnostics ASX:AT1 Equity ASA

John Kelly is a founder and Managing Director of Atomo. He came into diagnostics with a track record of radically transforming the user experience and health outcomes in the medical device field. Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. It is headquartered in Australia with global operations, arming consumers with simple to use, fast, accurate diagnoses and a seamless pathway to treatment, empowering patients to live healthier, more informed lives and making healthcare more accessible.
Atomo was founded by a grant from the Bill & Melinda Gates Foundation. The RDT devices were originally designed to easily diagnose HIV & malaria but has now been adapted for testing for Covid-19.
The guest and/or company has contributed to the cost of production.
IMPORTANT – Please remember these podcasts are produced to provide information and education and they are not designed to provide financial advice nor are they a recommendation to buy shares in the companies featured or discussed. ASA does not endorse or favour any specific commercial product or company. Please obtain independent professional advice before investing.
We value your feedback and questions. Please contact us at share@asa.asn.au if you have any suggestions for guests or specific questions you’d like answered.

Hosted on Acast. See acast.com/privacy for more information.